Prescription Drug Diversion Defense: Federal Charges Against Prescribers Explained

By Elizabeth Franklin-Best, Esq., and Christopher Zoukis, JD, MBA

Federal prescription drug diversion cases turn a profession into a target — the government prosecutes physicians, pharmacists, and other practitioners under the same drug-trafficking statute used against street dealers. If you are a prescriber, dispenser, or other professional facing a drug diversion investigation, you need a prescription drug fraud lawyer who can hold the government to what the Supreme Court now demands: proof of a culpable state of mind, not just a prescription it second-guesses. At Elizabeth Franklin-Best, P.C., we defend practitioners against federal prescription diversion allegations nationwide.

Prescription drug diversion is prosecuted under 21 U.S.C. § 841 — the same trafficking statute that anchors the other federal drug crimes — together with the registrant provisions of § 843. From “pill mill” indictments against entire clinics to single-prescriber prosecutions, the cases are document-intensive, expert-driven, and frequently combined with health care fraud counts.

That mix of trial defense, sentencing, and appellate work is exactly what a diversion case demands, and it is the work our firm concentrates on. Our principal attorney, Elizabeth Franklin-Best, has handled more than 330 federal proceedings — over 100 of them appeals — in United States district courts, in every one of the twelve federal courts of appeals, and at the United States Supreme Court, with particular depth in controlled-substance, sentencing, and post-conviction litigation. Chambers USA ranks the firm in 2026 for Litigation: White-Collar Crime & Government Investigations, and the 2026 Best Lawyers in America list names her a “Best Lawyer” in Appellate Practice. We approach every diversion case by holding the government to the demanding mental-state requirement the Supreme Court has now confirmed. If a diversion investigation or charge has reached your practice, begin with a paid, one-hour initial consultation.

Prescription Drug Diversion: Quick Answer

Question	Answer
What is prescription drug diversion?	Prescribing or dispensing controlled substances outside the bounds of legitimate medical practice — prosecuted under the federal drug-trafficking statute, 21 U.S.C. § 841.
What must the government prove?	That the practitioner knowingly or intentionally prescribed in an unauthorized manner — not merely that a prescription was, in hindsight, improper.
What penalties can apply?	The same penalties as drug trafficking — driven by drug type and quantity, including potential mandatory minimums.
Is bad medicine a crime?	No. Negligence, poor practice, or a treatment decision the government disagrees with is not a crime without the required culpable mental state.
How do we begin?	With a paid, one-hour initial consultation covering the records demand, the registration threat, and the criminal exposure together.

Key Takeaways

• Prescription drug diversion by practitioners is prosecuted under the federal drug-trafficking statute, 21 U.S.C. § 841, along with § 843.
• A practitioner is authorized to prescribe controlled substances only for a legitimate medical purpose in the usual course of professional practice.
• The Supreme Court held in Ruan that § 841’s “knowingly or intentionally” mens rea applies to the authorization question.
• The government must prove the practitioner knew the prescription was unauthorized, or intended to act in an unauthorized manner.
• It is not enough to show a prescription was, in hindsight, improper or outside the standard of care.
• Negligence, a good-faith treatment decision, or a disagreement with the government’s expert is not a crime.
• Diversion cases are expert-driven and frequently combined with health care fraud counts.
• The mens rea requirement confirmed in Ruan is the central defense for a prescriber.

What Is Prescription Drug Diversion?

Prescription drug diversion refers to controlled substances being channeled out of legitimate medical use and into misuse or illicit distribution. In healthcare enforcement, “drug diversion” is the umbrella term for any movement of controlled substances outside lawful channels — by patients, by employees, or by the professionals who prescribe and dispense them. When the government prosecutes a practitioner for diversion, the theory is that a physician, pharmacist, nurse practitioner, or other registrant prescribed or dispensed controlled substances outside the bounds of legitimate medical practice.

The legal mechanism is striking. Practitioners who hold a DEA registration are authorized to prescribe and dispense controlled substances — that authorization is what makes ordinary medicine possible. But that authorization has limits. Under 21 C.F.R. § 1306.04(a), a prescription for a controlled substance is valid only if it is “issued for a legitimate medical purpose by an individual practitioner acting in the usual course of his professional practice.” A prescription that lacks a legitimate medical purpose, or that is outside the usual course of professional practice, falls outside the authorization.

And when a prescription falls outside the authorization, the government prosecutes the practitioner under 21 U.S.C. § 841 — the very same drug-trafficking statute used against street-level dealers. A doctor accused of diversion is, in the eyes of the indictment, a drug trafficker. That framing is harsh, and it makes the practitioner’s state of mind the decisive issue.

The Ruan Standard: What the Government Must Prove

The most important development in prescription diversion law is the Supreme Court’s decision in Ruan v. United States, 597 U.S. 450 (2022), and every practitioner facing a diversion charge should understand it.

Section 841 makes it unlawful, “except as authorized,” to dispense a controlled substance. The question in Ruan was about a practitioner’s state of mind: to convict a doctor, is it enough for the government to prove that a prescription was, in fact, not authorized — or must the government prove something about what the doctor knew or intended?

The Supreme Court held that § 841’s “knowingly or intentionally” mens rea applies to the “except as authorized” clause. That means, to convict a practitioner, the government must prove beyond a reasonable doubt that the practitioner knew the prescription was unauthorized, or intended to act in an unauthorized manner. It is not enough to show — even with expert testimony — that the prescription was objectively improper, outside the standard of care, or not for a legitimate medical purpose. The government must prove the practitioner’s culpable state of mind.

Ruan also allocates the burdens in the defense’s favor. Once a defendant produces evidence that the prescribing was authorized — a prescription written by a registered practitioner — the burden falls on the government to prove the culpable mental state beyond a reasonable doubt. And because the decision resolved the consolidated appeals of two physicians, it swept aside jury instructions in several circuits that had allowed conviction on a purely objective “reasonable doctor” standard. What controls now is the defendant’s own state of mind, not a hypothetical practitioner’s.

This is a powerful, statute-level defense. It draws a firm line between a doctor who deliberately ran a pill operation and a doctor who made treatment decisions in good faith — even debatable ones. The government must establish criminal intent, not just second-guess medicine.

Applied Insight: After Ruan, the diversion defense centers on good faith. A practitioner who genuinely believed they were treating patients appropriately — even if a government expert later disagrees with those judgments — has not committed a crime. The defense develops the contemporaneous record of the practitioner’s clinical reasoning, because that record is the answer to the intent the government must now prove.

How Prescription Diversion Is Charged

Federal prescription diversion cases against practitioners are built from several statutes:

• Unlawful distribution, 21 U.S.C. § 841. The core charge — prescribing or dispensing a controlled substance outside the authorization, prosecuted as drug distribution.
• Registrant offenses, 21 U.S.C. § 843. Prohibited acts by registrants, including the use of fraud or material misrepresentation to obtain controlled substances and the use of a registration number in an unauthorized way.
• Drug conspiracy, 21 U.S.C. § 846. Where the government alleges an agreement among prescribers, staff, pharmacists, or others — the standard structure of a pill-mill indictment.
• Health care fraud and related offenses. Where controlled substances were billed to insurers or federal health care programs, diversion cases frequently carry health care fraud and Anti-Kickback Statute counts.
• Money laundering and, in the most serious cases, an offense resulting in death. Where a death is alleged to have resulted from a diverted prescription, the exposure rises dramatically.

Because diversion cases sit at the intersection of drug law and health care law, they require a defense that understands both — and that can manage parallel administrative exposure to the practitioner’s registration and license.

How the Government Builds a Diversion Case

Prescription diversion cases are intensely document- and data-driven. The government draws on prescription drug monitoring program data, pharmacy records, billing records, patient files, and the practitioner’s prescribing patterns over time. It frequently uses undercover patients, cooperating former patients or staff, and — central to every diversion case — a medical expert who testifies that the prescriptions fell outside legitimate practice. In the cases the government brands “pill mills” — high-volume clinics alleged to sell prescriptions rather than practice medicine — agents add financial analysis, employee cooperators, and clinic-wide prescribing statistics to that file, and they often charge the clinic’s owners, prescribers, and staff together as a conspiracy.

The “red flags” the government emphasizes — high volumes, large doses, dangerous drug combinations, cash payments, long patient travel distances, minimal examinations — are real patterns prosecutors point to. But after Ruan, the critical question is what those patterns prove. They are evidence the government will use to argue the practitioner knew the prescriptions were unauthorized. The defense answers with the practitioner’s own contemporaneous records, the legitimate clinical reasons for the prescribing, the realities of treating chronic pain and complex patients, and a defense expert who can testify that the care was within the bounds of legitimate practice — or at least that the practitioner reasonably and in good faith believed it was.

Applied Insight: Diversion cases are battles of experts, but Ruan reframed what the experts are fighting about. The question is no longer simply “was this good medicine?” It is “did this practitioner know they were acting outside authorization?” A defense expert who can explain the legitimate clinical basis for the prescribing speaks directly to the good faith that defeats criminal intent.

Penalties for Prescription Diversion

Because diversion is prosecuted under the trafficking statute, its penalties are the trafficking penalties — driven by drug type and quantity. Depending on the controlled substances and amounts involved, a diversion conviction can carry substantial prison terms and, in larger cases, mandatory minimums. Where the government alleges that death or serious bodily injury resulted from a diverted prescription, § 841(b) escalates the exposure sharply — a twenty-year mandatory minimum with a maximum of life. That enhancement has a real limit: under Burrage v. United States, 571 U.S. 204 (2014), the government must prove to the jury that the prescribed drug was a but-for cause of the death — a demanding causation standard that frequently fails in mixed-drug overdose cases.

The consequences extend well beyond the criminal sentence. A practitioner facing a diversion case also faces the loss of their federal registration to prescribe controlled substances, state medical or pharmacy board discipline up to the loss of licensure, exclusion from federal health care programs, civil liability, and the effective end of a career. The administrative and licensing exposure often moves on its own timeline and must be defended in coordination with the criminal case. One asymmetry deserves emphasis: the subjective-intent protection of Ruan governs the criminal case, not the administrative one — DEA can suspend or revoke a registration on a far lower showing.

In federal court, the advisory United States Sentencing Guidelines drive the sentence, with drug quantity under the § 2D1.1 table, loss where health care fraud is charged, the number of patients, and any resulting harm as central factors. For opioid cases, quantity is typically aggregated across every prescription the government deems illegitimate and converted through morphine-milligram-equivalent math — which makes the line between lawful and unlawful prescribing a sentencing battle, not only a guilt-phase one. Contesting those calculations is an essential part of any sentencing defense.

What Changed in Diversion Enforcement (2023–2026)

Practitioner prosecutions sit at a moving intersection of criminal law, agency rulemaking, and sentencing policy. Three currents matter most right now:

• Courts are still absorbing Ruan. Since 2022, the circuits have been rewriting good-faith and authorization instructions to match the subjective standard, and convictions built on purely objective “standard of care” instructions remain a live source of appellate and post-conviction litigation. On remand in Ruan‘s own companion case, the Tenth Circuit in United States v. Kahn, 58 F.4th 1308 (10th Cir. 2023), vacated a physician’s convictions across the board — including distribution and continuing-criminal-enterprise counts — because the erroneous good-faith instruction was not harmless where intent was genuinely contested.
• Telemedicine prescribing rules remain in flux. DEA and HHS extended the COVID-era telemedicine flexibilities for controlled-substance prescribing a fourth time — through December 31, 2026 — while finalizing rules for buprenorphine treatment via telemedicine in early 2025. Prosecutors continue to charge telehealth prescribers whose encounters allegedly lacked a legitimate medical purpose, so the boundaries of compliant virtual prescribing matter enormously.
• Sentencing turned slightly toward first-time professionals. Because most practitioner defendants have no criminal record, the retroactive zero-point offender reduction of Amendment 821 (effective November 1, 2023) and the exclusion of acquitted conduct under Amendment 826 (effective November 1, 2024) both land with particular force in diversion sentencings.

None of this softens the government’s posture — diversion enforcement remains a DEA and DOJ priority — but each development hands the defense another tool, provided counsel knows to use it.

Defenses to Prescription Diversion Charges

Every diversion prosecution turns on its records, so no honest lawyer guarantees an outcome before reading them. These are the themes that recur in practitioner defenses:

• Good faith. The practitioner genuinely believed the prescriptions were appropriate medical treatment — the central defense after Ruan.
• No culpable mental state. The government cannot prove the practitioner knew the prescriptions were unauthorized or intended to act in an unauthorized manner.
• Within legitimate practice. The prescribing was for a legitimate medical purpose in the usual course of professional practice — supported by the patient records and a defense expert.
• Negligence, not crime. Poor practice, recordkeeping lapses, or treatment decisions the government disputes are not crimes without criminal intent.
• Expert disagreement. A genuine, good-faith disagreement among medical experts about appropriate treatment does not establish a crime.
• Reliance and circumstances. The practitioner reasonably relied on patients, on referrals, or on the information available, and treated genuinely difficult patients.
• Quantity and causation challenges. The drug quantities attributed, and any claimed resulting harm, can be contested.
• Fourth Amendment and process challenges. The manner in which records were obtained, and other procedural issues, can be litigated.

The charts, the monitoring-program data, and the practitioner’s contemporaneous notes decide which of these themes carries the case. We work from those records outward — through the investigation, motions practice, trial, and appeal — pressing the mental-state requirement at every stage.

How Diversion Investigations Begin

Prescription diversion investigations arise from prescription drug monitoring data that flags a practitioner’s prescribing patterns, from pharmacy and insurer referrals, from regulatory inspections of a registrant, from patient or former-staff complaints, from undercover operations, and from broader health care fraud investigations. The first sign is often a regulatory inspection, a records demand, or an interview request. What follows that first contact tracks the stages laid out in our federal criminal process guide.

The early steps matter, and they are specific to practitioners. Preserve all patient records and practice documentation. Be cautious about administrative interviews and registration proceedings, which can generate statements usable in a criminal case. Decline to give an unprepared interview, and consult an experienced prescription drug fraud lawyer before responding — because the criminal case and the threat to the practitioner’s registration and license must be managed together from the start.

Why Work With Elizabeth Franklin-Best, P.C.

Prescription diversion cases reward defense lawyers who understand both drug law and health care law, who know the Ruan mens rea standard and how to build a good-faith defense, and who can coordinate the criminal case with the threat to a practitioner’s registration and license.

Elizabeth Franklin-Best — admitted to the U.S. Supreme Court and all twelve federal circuit courts of appeals, appearing pro hac vice in district courts around the country, and the author of Reversing Your Criminal Conviction — leads the defense. Christopher Zoukis, our Managing Director, handles the sentencing and Bureau of Prisons dimensions that hang over any practitioner facing a quantity-driven Guidelines range. Physicians, pharmacists, and nurse practitioners get a defense built for the courtroom and the agency proceeding at once.

What we offer is not a promised result. It is a defense that reads every chart, audits the government’s expert against the actual records, and treats your license and DEA registration as part of the case rather than an afterthought. That work starts with a paid, one-hour initial consultation.

Talk With a Prescription Drug Diversion Defense Lawyer

Liberty, registration, licensure, career — a diversion case threatens all four at once, and the record that protects them gets built early or not at all. Bring the matter to a prescription drug fraud lawyer at our firm through a paid, one-hour initial consultation, and we will tell you candidly where things stand.